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Chronic myelogenous leukaemia (CML) results from the Bcr-
Abl oncoprotein, which has a constitutively activated Abl
tyrosine kinase domain. Although most chronic phase CML
patients treated with imatinib as ﬁrst-line therapy maintain
excellent durable responses, patients who have progressed to
advanced-stage CML frequently fail to respond or lose their
response to therapy owing to the emergence of drug-resistant
mutants of the protein. More than 40 such point mutations
have been observed in imatinib-resistant patients. The crystal
structures of wild-type and mutant Abl kinase in complex with
imatinib and other small-molecule Abl inhibitors were
determined, with the aim of understanding the molecular
basis of resistance and to aid in the design and optimization of
inhibitors active against the resistance mutants. These results
are presented in a way which illustrates the approaches used
to generate multiple structures, the type of information that
can be gained and the way that this information is used to
support drug discovery.
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1. Introduction
Chronic myelogenous leukaemia (CML) results from a gene
defect in a haematological stem cell (HSC) leading to the
expression of the BCR-Abl oncoprotein (Ren, 2005). In
contrast to the tightly regulated c-Abl kinase, an auto-
regulatory domain in the oncoprotein is truncated, leading to
constitutive activation of the tyrosine kinase activity (Fig. 1).
The resulting unregulated phosphorylation of intracellular
proteins in HSCs leads to the uncontrolled growth and
survival of the leukaemic cells.
Imatinib (Gleevec; Novartis Pharma AG) is an inhibitor of
the Abl tyrosine kinase and the therapeutic concept of Bcr-
Abl tyrosine kinase inhibition as a treatment modality for
CML has been established with this drug (Baccarani et al.,
2006). In the great majority of chronic phase CML patients,
imatinib therapy affords progression-free survival with
durable haematological or cytogenetic responses. However,
the disease is not eradicated and a small percentage of patients
develop insensitivity to imatinib and relapse (Druker, 2006).
Relapse is frequently a consequence of the expression of
imatinib-resistant mutant forms of BCR-Abl, which escape
inhibition through the exchange of amino-acid residues in the
Abl kinase domain with alternative residues which maintain
enzymatic activity but have a reduced binding afﬁnity to
imatinib.
The good understanding of imatinib therapy has greatly
beneﬁtted from crystallographic studies of the Abl kinase
domain (Schindler et al., 2000; Nagar et al., 2002; Manley et al.,
2002), which showed that the drug inhibited the catalyticactivity of Bcr-Abl by binding to an inactive conformation of
the Abl kinase domain. Further structural biology studies
established the mechanisms whereby mutant forms of the
oncoprotein were resistant to imatinib (Gorre et al., 2001;
Cowan-Jacob et al., 2004). This has paved the way for the
design of second-generation Bcr-Abl inhibitors designed to
inhibit the wild-type kinase and maintain activity against the
imatinib-resistant mutants. It is believed that these new drugs
will beneﬁt imatinib-resistant and imatinib-intolerant CML
patients and, if used in combination with other distinct
Bcr-Abl inhibitors, might circumvent the emergence of drug-
resistant mutant forms of Bcr-Abl.
Crystallographic studies were undertaken in order to
contribute to drug-discovery efforts to ﬁnd new compounds
that might inhibit Bcr-Abl with higher afﬁnity while retaining
the excellent kinase selectivity proﬁle of imatinib. These
studies included determining the
binding modes of established chemo-
types in order to understand the reasons
for selectivity towards other kinases and
towards particular Bcr-Abl mutants.
Structures with novel chemotypes were
also determined to investigate the
conformational ﬂexibility of Abl kinase
and to identify potential new inter-
actions which could be used to increase
potency. These structures were followed
up by cocrystal structures with modiﬁed
chemotypes to support medicinal
chemistry as part of the structure-based
drug-design cycle involving computer-
aided design, chemistry, biochemistry,
biology and crystallography. In this
article, we present the approaches used
to obtain multiple cocrystal structures
with Abl kinase, the type of information
obtained and how this information was
used to support drug discovery. The
chemical structures of the compounds
discussed in this report are shown in
Fig. 1(b).
2. Experimental
2.1. Molecular biology and expression
Three different constructs of Abl
kinase were used in these studies.
Construct A was a gift from Brian
Druker, Oregon Health Sciences
University (USA). It consists of resi-
dues 218–500 of the 1130 amino acids
of full-length human c-Abl, with an
N-terminal His tag and a factor Xa
cleavage site (Fig. 1). Proteolytic
cleavage with factor Xa leaves four
extraneous amino acids (AAMD) at the
N-terminus. Construct B was a gift from Kuriyan and co-
workers (Schindler et al., 2000) and contains residues 229–515
of mouse c-Abl with an N-terminal His tag and a TEV
protease cleavage site. The proteolytic cleavage product in this
case contains six extraneous residues at the N-terminus
(GAMDPS). Construct C was designed based on the results
obtained with construct A and the published results with
construct B. Both the N-terminus and the C-terminus were
truncated to give residues 229–500 of human c-Abl with an
N-terminal His-tag and a TEV protease cleavage site. In this
case, the proteolytic cleavage product has ﬁve extra residues
(GAMDP) at the N-terminus (Fig. 1).
For construct C, the DNA fragment encoding amino acids
229–500 of human Abl was generated by PCR using pC3-
DNA-c-Abl (B. Druker) as a template. The PCR product was
inserted into the vector pFastBac-HTA (Invitrogen) using
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Figure 1
(a) Schematic diagram showing the relationship between Abl and Bcr-Abl (top), the constructs used
for crystallography (middle) and the amino-acid numbers for structural elements mentioned in the
text (bottom). The breakpoint cluster region (Bcr) is shown in red and the Abl gene is shown in light
blue. The green segment shows the Abl-SH2-binding region of Bcr that, when phosphorylated, is
necessary for the activation of the Abl tyrosine kinase (yellow boxes). The blue segment shows the
region of the Abl gene that is lost during the reciprocal translocation, which is involved in the down-
regulation of the Abl kinase. (b) Chemical structures of compounds mentioned in the text. 1, NVP-
AFN941; 2, imatinib; 3, NVP-AFG210; 4, PD180970; 5, NVP-AEG082; 6, nilotinib.restriction sites BamHI and HindIII. Automated sequencing
of plasmid DNA conﬁrmed the expected sequence of
the plasmid pFB-HTA-Abl500. Recombinant baculovirus
FB-HTA-Abl500 was generated using the conventional Bac-
to-Bac method from Invitrogen.
Recombinant protein was expressed in Sf9 cells cultured in
Excell 400 medium and 5% FCS in an 8 l total volume bio-
reactor (FairMenTec GmbH, Germany). The O2 level was
36% saturation and the culture temperature was maintained at
301 K. At 72 h post-infection, cells were pelleted and stored at
203 K. To produce Abl–inhibitor complexes during expres-
sion, some compounds were added at the time of infection
(imatinib, PD180970; 20 mM each) or 24 h before cell harvest
(NVP-AFN941; 3 mM).
2.2. Protein purification
All puriﬁcation steps were performed at 277–279 K. Cells
from one bioreactor were lysed by sonication in 200–300 ml
buffer A [50 mM sodium phosphate, 10%(v/v) glycerol, 0.3 M
NaCl, 10 mM 2-mercaptoethanol pH 8] supplemented with a
protease-inhibitor cocktail (Complete EDTA-free, Roche).
The lysate was clariﬁed by centrifugation and ﬁltration.
Compounds that had not already been added during
fermentation (e.g. NVP-AEG082, NVP-AFG210) were added
to the lysis supernatant (25 mM ﬁnal concentration) and the
His-Abl–ligand complexes captured by Ni-afﬁnity using Ni–
NTA Superﬂow resin (Quiagen) by either a batch or a column
procedure. After washing with low concentrations of imida-
zole (10–20 mM), His-Abl was eluted with 120–150 mM
imidazole in buffer B [20 mM Tris, 10%(v/v) glycerol, 0.1 M
NaCl, 5 mM 2-mercaptoethanol pH 8 at 277 K]. Subsequently,
2m M DTT and 1 mM EDTA were added and the His tag
removed by a 16–20 h incubation with TEV protease (80–
100 U per milligram of mg His-Abl; Invitrogen) in the case of
constructs B and C. Construct A was treated with 0.1%(w/w)
papain (Roche) for 3.5 h to remove the His tag together with
the factor Xa site and amino acids 219–227 of Abl. The papain
reaction was stopped by the addition of 25 mgm l
1 antipain
(Roche). The cleavage reactions, except for that of the Abl–
NVP-AFN941 complex, were puriﬁed by anion-exchange
chromatography on a Mono Q HR10/10 column (GE
Healthcare) using a gradient from 50 to 300 mM NaCl in
buffer C [20 mM Tris, 5%(v/v) glycerol pH 8.4 at 277 K]. Prior
to loading, the respective ligands were re-added to a 1.5-fold
molar excess to stabilize the Abl kinase during this step. The
main peak containing unphosphorylated Abl either still in
complex with the respective ligand (imatinib, PD180970,
NVP-AEG210) or in the apo form owing to ligand loss (NVP-
AFG210) were concentrated after re-addition of enough
ligand to obtain a twofold molar excess and applied onto a
HiLoad 16/60 Superdex 75 size-exclusion column (GE
Healthcare). The column was eluted with buffer D (20 mM
Tris, 0.1 M NaCl, 1 mM EDTA, 3 mM DTT pH 7.6 at 296 K)
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Table 1
Crystallization and data-collection statistics.
Values in parentheses are for the highest resolution shell.
Crystal complex Imatinib NVP-AEG082 NVP-AFN941 NVP-AFG210 PD180970
Construct A (papain-cleaved) A (papain-cleaved) A (papain-cleaved) BC
Protein concentration
(mg ml
1)
25 30 24 25 28
Initial Screen hit Hampton Research
Crystal Screen 1
No. 18
Hampton Research
Crystal Screen 1
No. 22
Novartis Screen K
No. 9
Hampton Research
Crystal Screen 1
No. 46
Hampton Research
Crystal Screen 1
No. 7
Crystallization buffer 16% PEG 8000,
0.1 M MES pH 6.75,
0.2 M Mg(OAc)2
28% PEG 4000, 0.1 M
Tris–HCl pH 8.0,
0.2 M NaOAc
12% PEG 8000, 0.1 M
HEPES pH 7.5,
0.2 M Mg(OAc)2
16% PEG 8000, 0.1 M
Na cacodylate pH 6.2,
0.2 M Mg(OAc)2
0.9 M NaOAc, 0.1 M
Na cacodylate
pH 7.0
Cryobuffer 30% glycerol 15% glycerol 25% glycerol 20% glycerol 30% glycerol
Microseeding Yes No Yes Yes No
Method Hanging-drop
vapour diffusion
Hanging-drop
vapour diffusion
Hanging-drop
vapour diffusion
Microbatch under oil Hanging-drop
vapour diffusion
Crystallization
temperature (K)
277 293 277 277 277
Synchrotron source DESY BW7B ESRF SNBL SLS PX 06 SLS PX 06 ESRF ID14-1
Temperature (K) 100 100 100 94 100
Wavelength (A ˚ ) 0.8452 0.8000 0.9778 0.8602 0.934
Detector MAR300 MAR345 DTB MAR CCD 165 MAR CCD 165 MAR CCD 165
Space group C2221 P212121 C2 I4122 P21212
Unit-cell parameters
(A ˚ )
a = 141.7, b = 148.7,
c = 115.3
a = 34.0, b = 124.1,
c = 139.5
a = 185.4, b = 58.9,
c = 104.0
a = 105.4, b = 105.4,
c = 110.4
a = 106.5, b = 131.5,
c = 56.5
Molecules in the ASU 4231 2
VM (A ˚ 3 Da
1) 2.4 2.3 2.6 2.4 3.1
Solvent content (%) 49 47 53 49 60
Resolution range (A ˚ ) 25.0–2.4 (2.49–2.40) 25.0–2.1 (2.18–2.10) 40.0–2.8 (2.90–2.80) 32.0–2.7 (2.80–2.70) 34.3–1.7 (1.79–1.70)
Rmerge 0.055 (0.438) 0.087 (0.252) 0.087 (0.335) 0.036 (0.479) 0.070 (0.424)
Completeness (%) 99.5 (100.0) 99.8 (99.9) 96.2 (83.3) 96.0 (60.8) 99.5 (100.0)
Unique reﬂections 47314 35534 22731 17626 87524
Multiplicity 4.1 6.1 2.8 4.0 4.8
Processing program DENZO/SCALEPACK DENZO/SCALEPACK DENZO/SCALEPACK DENZO/SCALEPACK MOSFLMand the peak corresponding to a monomeric Abl–ligand
complex collected. Ligands were re-added if they were
partially lost during the size-exclusion step (NVP-AFG210,
NVP-AFN941) and the Abl–ligand complexes concentrated to
23–30 mg ml
1 by ultraﬁltration. In the case of Abl–NVP-
AFN941, T-cell protein tyrosine phosphatase (27 units per
milligram of Abl; New England Biolabs) was added to the
papain cleavage reaction after stopping with antipain and the
mixture was incubated for an additional 20 h at 277 K. The
Mono Q step was omitted and the concentrated reaction was
directly applied onto Superdex 75 and eluted with a modiﬁed
buffer D which includes 0.2 M ethyleneglycol. The concen-
trations of Abl and the respective ligands were determined by
HPLC. The puriﬁed Abl–ligand complexes were characterized
by mass spectrometry (LC–MS) and N-terminal sequence
analysis.
2.3. Crystallization and data collection
Crystal screening was ﬁrst performed manually using
hanging-drop experiments with approximately 0.8 + 0.8 ml
drops in 24-well trays and later using automated methods
where sitting drops as small as 0.2 + 0.2 ml were prepared using
an eight-tip pipetting system (Cartesian) in 96-well trays. To
maximize the chances of success, owing to the comple-
mentarity of the results obtained by different crystallization
methods, microbatch under oil was also used for screening
(OryX, Douglas Instruments, UK). Commercial screens from
Hampton Research (Laguna Niguel, CA, USA) and Jena
Bioscience (Jena, Germany) were used in addition to home-
made screens, which were designed based on crystallization
buffers shown to be successful with other proteins in published
or internal reports. Screens were performed at 277 and at
293 K, with protein concentrations between 15 and
30 mg ml
1, depending on the behaviour of the particular
complex. Optimization was performed
by the hanging-drop method in 24-well
plates or by microbatch under oil in 72-
well plates.
In many cases, seeding of the opti-
mization experiments was performed by
touching available crystals with a cat
whisker or a disposable acupuncture
needle and then touching successive
freshly set drops with the probe. In one
example (the imatinib complex), crys-
tals obtained at 293 K did not diffract
well, but seeding from these crystals
into drops set up with the same buffer
conditions at 277 K gave a new crystal
form which diffracted to beyond 2.4 A ˚
resolution.
Crystals obtained were always cryo-
cooled in order to avoid serious radia-
tion damage and also because many of
the crystals were obtained at 277 K.
This was performed by gradual addition
of a cryobuffer, which was usually equivalent to the mother
liquor but with some of the water replaced by glycerol. The
addition of cryobuffer had to be gradual in order to avoid
damaging the crystals and generally took 2–4 h. The last step
was a transfer of the crystal into the cryobuffer and then a
quick dunking of the crystal on a loop into liquid nitrogen. All
data sets were collected at synchrotron sources and the results
for the examples mentioned in this report are listed in Table 1.
2.4. Structure determination and refinement
Structures were determined using MOLREP from the
CCP4 program interface CCP4i (Vagin & Teplyakov, 1997;
Collaborative Computational Project, Number 4, 1994), initi-
ally using the protein coordinates of PDB entry 1fpu
(Schindler et al., 2000) and then using the most similar struc-
tures obtained in our laboratory. Rigid-body reﬁnement of the
solutions was performed using REFMAC5 (Murshudov et al.,
1997), restrained reﬁnement using maximum-likelihood
statistics was carried out using REFMAC5 or an early version
of BUSTER (Roversi et al., 2000; Blanc et al., 2004) and model
building was performed using the program O (Jones et al.,
1991). Strong noncrystallographic symmetry restraints were
used in the initial cycles of reﬁnement, but the number of
restraints was reduced as reﬁnement proceeded to account for
real differences between the molecules. Individual B factors
were reﬁned throughout the process. The ﬁnal cycles of
reﬁnement, performed using REFMAC5 in all cases except for
the Abl–NVP-AFG210 complex, were interfaced with water
addition using ARP/wARP (Perrakis et al., 1997). Structure
validation was performed using tools in the programs O and
PROCHECK (Laskowski et al., 1993). All ﬁgures were
prepared using PyMOL (http://pymol.sourceforge.net). PDB
access codes for the structure factors and coordinates of the
ﬁnal models are listed in Table 2.
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Table 2
Reﬁnement statistics and inhibition constants.
Compound Imatinib NVP-AEG082 NVP-AFN941 NVP-AFG210 PD180970
IC50†( n M)
Wild-type Abl 170  23 330  113 3425  1075 41 (n =1 ) 7 0 32
Bcr-Abl 231  43 565  60 30% at 3 mM >700 22  2
Contents of model
Protein atoms 2071, 2098,
2081, 2098
2121, 1966 2139, 2134,
2115
2182 2210, 2117
Inhibitor atoms 37, 37, 37, 37 31, 31 35, 35, 35 27 29, 29
Water molecules 200 387 19 0 540
R factor 0.208 0.195 0.218 0.264 0.176
Free R factor 0.260 0.256 0.287 0.314 0.204
R.m.s.d. bonds (A ˚ ) 0.02 0.03 0.02 0.01 0.02
R.m.s.d. angles () 1.86 1.57 1.87 1.16 1.69
Ramachandran plot (%)
Most favoured 88.1 87.6 86.3 84.6 88.8
Allowed 11.0 11.1 13.3 13.3 11.2
Generously allowed 0.9 1.1 0.4 2.1 0.0
Disallowed 0.0 0.2‡ 0.0 0.0 0.0
PDB code 2hyy 2hz0 2hz4 2hzn 2hzi
†I C 50 values represent the inhibitor concentrations required to inhibit activity by 50% (proliferation of Bcr-Abl-
dependent murine haematopoietic Ba/F3 cells; for an overview, see Manley, Cowan-Jacob & Mestanet al.,
2005). ‡ A234-Lys, in weak density at the N-terminus.3. Results and discussion
3.1. Protein preparation
The three different constructs of Abl kinase prepared for
this study (Fig. 1) show similar behaviour. Expression in Sf9
insect cells yields around 10 mg soluble Abl protein per litre;
however, it is heterogenously phosphorylated. To obtain
homogeneous protein for crystallization, the unphosphor-
ylated form of Abl kinase is preferred. The fraction of
unphosphorylated protein can be increased through dephos-
phorylation by protein tyrosine-speciﬁc phosphatases or, more
convienientely, by including an Abl kinase inhibitor in the cell
culture. In several cases, the addition of inhibitor leads to an
increase in the expression level. However, inhibitor addition is
limited by the toxicity of the compound towards the insect
cells, e.g. NVP-AFN941 could only be added later during
expression and at low concentration, and by the stability of the
compound under fermentation conditions. Compounds
modiﬁed during fermentation (e.g. NVP-AEG082) had to be
added during cell lysis. All three constructs are labile in their
apo form, but can be stabilized by ligands, with the degree of
stabilization reﬂecting directly the afﬁnity of a particular
ligand towards Abl kinase. Stabilization by a high-afﬁnity
ligand is particularly crucial in the anion-exchange step used
to separate residual phosphorylated forms and to achieve high
protein concentrations for crystallization. Initially, protein
from construct A was puriﬁed and cleaved with factor Xa to
obtain AAMD-Abl(218–500), which crystallized readily in
complex with imatinib. However, these crystals diffracted
poorly, possibly owing to the elongated N-terminus compared
with that of construct B (Schindler et al., 2000). Limited
proteolysis with papain gave an N-terminally trunctated
protein Abl(227/228–500) which yielded high-resolution
structures with imatinib and NVP-AEG082. Based on this
result and the N-terminus reported for crystallized mouse-Abl
(construct B), construct C was designed. Construct B was
crystallized once (with NVP-AFG210) to compare it with the
in-house constructs A and C, but did not show any advantage.
An efﬁcient puriﬁcation procedure for construct C in the
presence of a stabilizing ligand has been established and has
allowed the preparation and crystallization of many different
complexes besides that reported here with PD180970.
3.2. Crystallization
Throughout the duration of this project, numerous reﬁne-
ments were made to the processes. Initially, screens were
performed with hanging-drop experiments in 24-well trays and
required about 100 ml protein to screen 96 different buffer
conditions. The more recent screens were prepared using a
robot to distribute the reservoir solutions (reformatting) into
96-well trays and another robot to prepare sitting drops in
these trays, requiring less than 30 ml of protein to test 96
different buffer conditions. Initially, viewing of plates was
performed manually under a microscope, but more recently
the introduction of an automated imaging system allowed the
viewing of trays stored at 277 and 293 K remotely according to
a predeﬁned schedule. The advantages of the robotics can be
measured in the larger number of experiments that can be
performed with the same amount of protein, the reduced
manual intervention time and the simultaneous electronic
recording of the experimental details and results.
Crystallization details for the structures published here are
listed in Table 1. Much better results were obtained with
crystallization of construct C compared with construct A and
in order to obtain diffraction-quality crystals with the former,
seeding was usually necessary. Among the trends noticed for
these and the many other Abl complexes crystallized was the
fact that the ease of crystallization (number and simplicity of
optimization of hits from crystal screens) increased in
proportion to the increase in afﬁnity of the inhibitor. The Abl
protein was found to be much less stable in the absence of an
inhibitor, tending to aggregate and precipitate. Presumably,
the higher afﬁnity inhibitors stabilized the protein, making it
more suitable for crystallization.
3.3. Structure determination and refinement
The phasing and reﬁnement of the structures presented
here was relatively straightforward, except for the NVP-
AFG210 and NVP-AFN941 complexes (Table 2, difference
maps for the ligands are shown in the supplementary mate-
rial
1). In the case of NVP-AFG210, the overall temperature
factor for the data based on Wilson statistics was estimated at
77 A ˚ 2 and the individual values reﬁned to an average of 80 A ˚ 2
for the protein, with a range of 33–175 A ˚ 2. The electron
density resembled that of a lower resolution structure, the
ligand occupancy was weak and the R factors converged at
rather high values (R = 0.264, Rfree = 0.314). Water molecules
were not added to the electron density owing to the low
resolution. Repeated data collection from different crystals
gave no improvement. The data were checked for twinning
and also processed in lower symmetry space groups, but no
errors could be identiﬁed. There are some close contacts
between the inhibitor and the protein and it should be
considered a low-quality structure from which only the mode
of binding and not detailed interactions can be inferred. In the
case of the Abl–NVP-AFN941 complex there was a technical
problem during collection of the data at the synchrotron, in
which the total ’ range of each image was actually shorter
than requested. This data collection was not repeated because
other structures had higher priority and the quality of the
electron density in this case was reasonable for the resolution
of the data obtained. The surprising result for this complex
was the fact that only one of the three molecules in the
asymmetric unit contained the inhibitor, despite the fact that
the crystallization was performed with astoichiometric ratio of
the protein and NVP-AFN941. The other two inhibitors were
found to form crystal contacts between protein molecules.
There is an ongoing debate in the pharmaceutical industry
about the balance between quality and impact in structural
biology. Considerable efforts can be made to try and improve
research papers
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1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: BA5102). Services for accessing this material are described at the
back of the journal.the crystals in order to obtain higher resolution data, to
recollect data sets that have lower quality owing to a technical
problem (e.g. the short ’ range in the NVP-AFN941 complex
data set) and to reﬁne the structure to a point where even the
most meticulous crystallographer would not ﬁnd a better ﬁt.
However, what level of quality is really required to be sure
that one has an accurate model of the inhibitor binding to the
protein target which can be used as a basis for drug design?
Some groups only spend time reﬁning the part of the structure
close to the ligand-binding site, which in general gives an
accurate result when the quality of the data is high and when
multiple structures of the same protein have already led to a
very good model. We tend to reﬁne all structures to conver-
gence, especially in a case like this where many different space
groups are found and different crystal environments lead to
many different loop conformations, as Abl kinase is a rather
ﬂexible protein. However, if repeating the experiment
requires going back to protein expression in the presence of
the inhibitor, or if obtaining better data means going back to
screening to ﬁnd a new crystal form, and if the quality of the
data are sufﬁcient to be sure of the mode of binding of the
inhibitor, this extra work may not be justiﬁable in an envir-
onment where time and resources are critical. What is
important is to be able to recognize what level of detail the
quality of the structure is justiﬁed to provide and not to
overinterpret the results (Davis et al., 2003).
3.4. Structure of the imatinib complex and study of mutants
The structure of human Abl in complex with imatinib
(Manley et al., 2002) is very similar to the structure of the
mouse enzyme (Nagar et al., 2002), despite the fact that they
were obtained in different space groups and with different
length proteins (Fig. 1). The average r.m.s.d. value for all 261–
264 C
  atoms of pairwise superimposed subunits (four protein
molecules in the human structure, two in the mouse structure)
varies between 0.34 and 0.80 A ˚ . The main differences occur in
loop regions where the temperature factors are high (e.g. the
 3- C loop and the A-loop) and are not highly correlated with
crystal contacts. In general, there are slightly higher differ-
ences in the N-terminal lobe because there is a tendancy for
this lobe to rotate as a rigid body with respect to the
C-terminal lobe.
Imatinib binds in the cleft between the N- and C-terminal
lobes, as expected (Fig. 2). However, what was not predicted
before the des-methylpiperazinyl imatinib structure appeared
(Schindler et al., 2000) was that it bound to an inactive
conformation where the DFG motif ﬂips out to make a
channel beyond the gatekeeper residue (Thr315) for the
benzamide and N-methylpiperazine groups (Nagar et al., 2002;
Manley et al., 2002). The rest of the A-loop also adopts an
inactive conformation in which the residues around Tyr393
bind in and block the substrate-binding site. In addition, the
P-loop folds down to form a cage around the pyridine and
pyrimidine groups of imatinib. The N-methylpiperazine group,
which was incorporated into the molecule during optimization
to improve solubility, is found to have a strong interaction with
the protein via hydrogen bonds with the main-chain carbonyl
groups of Ile360 and His361 (Fig. 2). Other hydrogen-bond
interactions are found between the pyridine N and the back-
bone NH of Met318 in the hinge region, the anilino NH and
the side chain of the gatekeeper residue Thr315, the amide NH
and the side chain of Glu286 from helix C, and the amide
carbonyl and the backbone NH of Ala380, which just precedes
research papers
Acta Cryst. (2007). D63, 80–93 Cowan-Jacob et al.  Drug discovery 85
Figure 2
(a) Ribbon diagram showing the binding of imatinib (green C atoms) to Abl kinase (helices in red, strands in blue, loops and turns in grey), with the
locations of mutants isolated from imatinib-resistant patients shown in yellow. (b) Details of the binding of imatinib (green C atoms) to Abl kinase (gray
C atoms) showing potential hydrogen bonds as orange dotted lines.the highly conserved DFG motif. These hydrogen bonds are
complemented by extensive hydrophobic interactions over the
whole length of the inhibitor, although there are less for the
N-methylpiperazine, which is partially exposed to solvent.
3.4.1. Reasons for selectivity. Determinants of selectivity in
Abl kinase include the conformation of the DFG motif at the
start of the A-loop and the conformation of the P-loop.
Kinases such as c-Src, that are presumably unable to adopt the
DFG-out conformation, cannot bind imatinib strongly
(Cowan-Jacob et al., 2005). c-Src shares a very high sequence
identity with Abl kinase (50% in the kinase domain and about
90% in the ATP site and around the DFG motif), but has a
different inactive kinase conformation compared with inactive
Abl in complex with imatinib (Xu et al., 1999; Nagar et al.,
2002, 2003). In the assembled inactive c-Src structure, the
C-helix is swung out of the active site and the A-loop forms a
single turn of helix that stabilizes the position of helix C by
packing underneath it. However, the DFG motif has a
conformation similar to that observed in active kinases. As a
result, imatinib or its analogues bind to c-Src or the homo-
logous Syk with a different and lower afﬁnity binding mode
(Cowan-Jacob et al., 2005; Atwell et al., 2004).
The DFG-out conformation has been seen for other kinases
such as the Ser/Thr kinases b-Raf (Wan et al., 2004) and P38
Map kinase (Pargellis et al., 2002), and the tyrosine kinases
cKit (Mol et al., 2004), KDR (Manley, Bold et al., 2004), Flt-3
(Grifﬁth et al., 2004) and insulin receptor kinase (Irk; Hubbard
et al., 1994). However, imatinib does not bind to b-Raf, P38,
KDR, Flt-3 or Irk, although it does bind to c-Kit. Therefore,
although the ability of the kinase to adopt the DFG-out
conformation is necessary for it to bind to imatinib, this is not
sufﬁcient. One of the reasons for this is the size of the side
chain in the gatekeeper position at the back of the ATP-
binding site. In Abl it is Thr315, while in Irk it is a methionine,
in Flt-3 it is a phenylalanine and in b-Raf it is a leucine. If these
side chains are larger than threonine, they partially block the
path to the pocket formed by the DFG-out conformation,
which restricts the types of compounds that can access this
pocket. In KDR this residue is a valine, which would not cause
steric hindrance, but would be unable to form a hydrogen
bond with imatinib. The reason for the lack of binding of
imatinib to P38 kinase, which, like Abl, has threonine in the
gatekeeper position, is the existance of a shorter hinge region
that changes the shape of the ATP-binding site. The fact that
imatinib is observed to bind to c-Kit suggested that c-Kit,
which also has a threonine in the gatekeeper position and
shares high homology to Abl in the ATP site and the DFG
region, can also adopt the DFG-out conformation and this was
recently conﬁrmed by Mol et al. (2004). Presumably PDGFR 
can adopt a similar conformation, although this structure has
not yet been published.
The P-loop (phosphate-binding or glycine-rich loop)
contributes to the selectivity because, as mentioned above, in
the imatinib complex this loop adopts an inactive conforma-
tion that forms extensive contacts with the inhibitor. This
conformation allows Tyr253 of the P-loop to form a face-to-
edge aromatic interaction with the pyrimidine group of
imatinib. A similar conformation has been seen in an Fgfr1
kinase–inhibitor complex, where it is also thought to contri-
bute to binding of the inhibitor and therefore selectivity
(Mohammadi et al., 1997). In the imatinib–c-Kit complex, the
conformation of the P-loop resembles that found in active
kinases. This is a consequence of the presence of a cysteine in
c-Kit in the place of Ala380 in Abl, which requires a different
conformation of the Phe382 side chain for steric reasons and
allows this side chain to form a face-to-edge aromatic inter-
action with imatinib (Mol et al., 2004; S. Cowan-Jacob & G.
Fendrich, unpublished data). At the same time, the Phe382
side chain prevents the P-loop from adopting the cage
conformation observed in c-Abl. Hence, imatinib will bind
strongly to kinases in which the P-loop sequence favours the
adoption of a conformation that allows extensive contacts with
the inhibitor, or in which other structural elements can form
similar interactions. The consequence of these observations
for the design of new inhibitors is that incorporating inter-
actions between the inhibitor and the protein that take
advantage of special inactive conformations of the kinase is
likely to provide selectivity.
3.4.2. Reasons for resistance. The single site mutations of
Bcr-Abl were mapped onto the imatinib–Abl complex struc-
ture as they were reported (Shah et al., 2002). The surprising
observation was that these mutations do not cluster around
the imatinib-binding site, but are spread throughout the kinase
domain (Fig. 2). The reasons for resistance have been
discussed in depth elsewhere (Cowan-Jacob et al., 2004), but
the general trends are summarized here. The commonest
mutations are Thr315Ile (the gatekeeper residue in the hinge
region), Glu255Lys/Val (in the P-loop) and Met351Thr
(distant from the binding site in the C-terminal lobe of the
kinase). The gatekeeper mutation causes steric hindrance with
imatinib and the loss of a hydrogen bond, which explains why
the afﬁnity of imatinib drops dramatically (IC50 >1 0mM for
Thr315Ile, compared with 0.20 mM for wt-Abl). The mutation
from threonine to isoleucine makes no difference to the
binding of ATP and there are quite a variety of residues found
in this position in other kinases in their wild-type state,
suggesting that this will be a hotspot for mutations causing
resistance to the binding of many inhibitors of kinases, even in
their active state. The P-loop mutation causes the loss of two
hydrogen bonds that stabilize the inactive conformation of this
special cage around the inhibitor and would therefore tend to
shift the equilibrium distribution of the kinase conformational
states towards the active conformation, to which imatinib does
not bind (IC50 =6 . 7mM for Glu255Lys). Other mutations in
the P-loop such as Tyr253His or Gly250Glu also cause
signiﬁcant insensitivity to inhibition by imatinib (IC50 >1 0mM
and 3 mM, respectively), also probably owing to either desta-
bilization of the inactive conformation or stabilization of the
active conformation of the kinase. For example, the glutamate
mutation at the position of Gly250 does not provide any
reason for destabilization of the inactive conformation of the
P-loop, but it could form hydrogen bonds that would stabilize
the conformation of the P-loop in the activated kinase. The
distant mutation Met351Thr is more difﬁcult to explain. A
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AMN107) shows that the mutation causes a small rearrange-
ment in the core of the C-terminal lobe of the kinase (Weis-
berg et al., 2005). This is likely to lead to a higher overall
entropy of the structure, which will require more energy for
inhibitor binding. In addition, it may lead to a shift in equili-
brium between the inactive and active conformations of the
kinase. All of these distant mutations, including some in the
A-loop such as His396Pro, have a relatively small effect on the
binding afﬁnity, with IC50 values only threefold to sixfold
higher than for wild-type Abl. A recent crystal structure of the
latter mutant revealed an active conformation of Abl kinase,
despite the lack of phosphorylation of the A-loop tyrosine
(Young et al., 2006). This is most likely owing to the
destabilization of the inactive conformation of the A-loop as a
consequence of the conformational constraints of the proline,
but may be enhanced by the fact that the inhibitor, VX-680,
sterically favours the active conformation.
The theory that many of these single-site mutations lead to
a shift of the Abl kinase conformation towards the active state
is supported by the work of Azam et al. (2003), in which an in
vitro screen was used to ﬁnd imatinib-resistant mutants in the
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Figure 3
(a) Ribbon diagrams showing the binding of NVP-AFN941 (top) and PD180970 (bottom) to Abl kinase. (b) Details of the binding of these two
compounds in the ATP site of Abl. Colour schemes are the same as in Fig. 2.kinase domain and the N-terminal region of
Abl. A mapping of these mutants onto the
structure of the assembled inactive state of
Abl, which includes the SH3, SH2, linker
and kinase domains, shows that many of
these mutants will interfere with the
domain–domain regulatory interactions that
are required to maintain the down-regulated
state of Abl (Nagar et al., 2003, 2006). Other
mutations would appear to disfavour an
Src-like inactive conformation of Abl that
might be necessary for the interconversion
between the active and inactive states
(Levinson et al., 2006).
The binding of imatinib to the inactive
conformation of Abl kinase relies on speciﬁc
interactions and conformational states that
in many cases have no constraints in the
active conformation. For example, the resi-
dues observed to be mutated in the P-loop
have no effect on the binding of ATP in the
active conformation and result in no signif-
icant change to the Km values, but the
identity of the residues is important for the
binding of imatinib because they contribute
to the stabilization of the inactive confor-
mation (Cowan-Jacob et al., 2004). There-
fore, the reasons for selectivity are also a
strong contributor to the susceptibility to
resistance.
3.5. Exploring the inhibitor-binding site
3.5.1. Structures of Abl in complex with
different chemotypes. An attractive
strategy to overcome or avoid most cases of resistance would
be to administer two drugs in combination which utilize
different binding interactions to inhibit the Abl kinase. In
particular, a useful combination could be a compound which
binds to the inactive conformation, such as imatinib, with a
compound which binds to an active conformation. Examples
of chemotypes used as leads for targeting the active confor-
mation are NVP-AFN941 (tetrahydrostaurosporin) and
PD180970 (Fig. 3). The structures of these complexes show
that both inhibitors bind in the ATP site and form hydrogen
bonds with the hinge region and that they are both within van
der Waals distance of the Thr315 gatekeeper residue, although
the contacts between PD180970 and Thr315 are much more
extensive. The NVP-AFN941 complex structure essentially
resembles that of an active kinase, despite the lack of phos-
phorylation on the A-loop, although some parts of the A-loop
and the P-loop are disordered in the crystals. This structure is
very similar to other structures of tyrosine kinases in complex
with staurosporin, such as Lck, Zap-70, Syk and Fyn (Zhu et
al., 1999; Jin et al., 2004; Atwell et al., 2004; Kinoshita et al.,
2006). There are only minor differences in distant loops and
the A-loop near the phosphorylation site, because some of
these structures are phosphorylated and the Abl–NVP-
AFN941 complex is not. The PD180970 structure, which is
similar to that of a complex with a related compound
published by Nagar et al. (2002), shows an inactive confor-
mation of the P-loop and an unusual conformation of the DFG
motif (Fig. 3), but otherwise resembles an active kinase
conformation with respect to the position of the C-helix and
the path of the rest of the A-loop. Tyr393 is sitting in the same
position as the phosphorylated tyrosine in active Lck and
there is room in this Abl structure for a phosphate group
which could interact with Arg363 and His396. The confor-
mation of the P-loop resembles that of the complex with
imatinib, which shows that this conformation can be adopted
with different chemotypes and it is not speciﬁcally stabilized
by imatinib only. The conformation of the DFG motif involves
the ﬂipping over of Asp381 to make a strong hydrogen bond
with the main-chain carbonyl of Val299 (Fig. 4). This results in
the Asp381 side chain occupying what would be the position
of the Phe382 side chain in the active conformation and the
Phe382 side chain ﬂipping over to occupy the site of the
Asp381 side chain. This ‘DFG-ﬂip’ conformation puts the
Phe382 side chain in van der Waals contact distance of the
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Figure 4
(a) Superposition of the four main DFG conformations observed in Abl kinase structures, with
the active conformation in cyan, the DFG-out conformation in yellow, the DFG-ﬂip
conformation in grey and the Src-like inactive conformation in green. (b) Superposition of all
structures reported here plus PDB entry 2g1t. The P-loop is shown in red, the C-helix is cyan,
the A-loop is blue and all the ligands are shown in green. The superposition is based on an
alignment of the C-terminal lobes to emphasize the relative differences in angles between the
N- and C-terminal lobes of the kinase. (c) A stereoview of all the ligands superimposed
(imatinib, magenta C atoms; NVP-AFN941, cyan C atoms; NVP-AFG210, yellow C atoms;
NVP-AEG082, green C atoms; PD180970, grey C atoms).inhibitor. The buffer used to grow the crystals of the Abl–
PD180970 complex crystals has a pH of 7.0 (measured as pH
6.8), so it is unlikely that it is the crystal buffer that favours
protonation of the Asp381 side chain, although it cannot be
ruled out that this conformation is an artefact of the crystal-
lization conditions. A similar conformation of the DFG motif
is seen in other Abl structures (Nagar et al., 2002, 2003) and it
may represent another natural inactive conformation of the
kinase. This ‘DFG-ﬂip’ conformation does not expose the
pocket beyond the gatekeeper residue that becomes available
for inhibitor binding in the ‘DFG-out’ conformation.
The structure in complex with NVP-AEG082 represents
that of a chemical class that binds to the inactive ‘DFG-out’
conformation of Abl kinase, but does not induce or stabilize
an inactive conformation of the P-loop (Fig. 5). The triﬂuoro-
methylphenyl group makes a very complementary ﬁt to the
‘DFG-out’ pocket and the reverse amide of NVP-AEG082
(compared with the orientation of the amide in imatinib) and
makes analogous hydrogen bonds to Glu286 and the amide N
atom of Ala380 to those observed for imatinib. As for most
other kinase inhibitors, NVP-AEG082 forms two hydrogen
bonds with the main-chain atoms of the hinge region. There
are two molecules in the asymmetric unit of the crystals and
one of these shows a novel A-loop conformation, while the
A-loop is not visible in the other owing to disorder. The novel
A-loop conformation lies in an intermediate position between
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Figure 5
(a) Ribbon diagrams showing the binding of NVP-AEG082 (top) and NVP-AFG210 (bottom) to Abl kinase. (b) Details of the binding of these two
compounds in the ATP site of Abl. Colour schemes are the same as in Fig. 2.the active conformation and the imatinib-bound conforma-
tion. The path of this segment departs from the latter
conformation at Leu383, superimposes again at Lys400, has
Tyr393 exposed at the surface and shows some weak resem-
blance to the intermediate conformation observed in partially
phosphorylated Igf1r kinase (Pautsch et al., 2001). However,
this conformation is stabilized by crystal contacts in the Abl
structure, so it is not clear if this is really a natural inactive
state of the A-loop of Abl kinase. Another difference between
the conformation of the protein in the NVP-AEG082 complex
and the imatinib complex is the relative position of the N- and
C-terminal lobes of the kinase. There is a shift of main-chain
atoms in the N-terminal lobe as great as 2.6 A ˚ between the two
structures. This seems to be induced by the differing shapes of
the inhibitors rather than crystal-packing forces, because both
molecules in the asymmetric unit of the NVP-AEG082
complex have different crystal-packing contacts, yet they both
have the same relative orientation of the N- and C-terminal
lobes.
NVP-AFG210, a known Raf kinase inhibitor (Thaimattam
et al., 2004) is another example of a compound that binds to
the DFG-out conformation of Abl kinase. This chemotype is
interesting because it would be predicted to bind to the
Thr315Ile gatekeeper mutant and although this particular
compound was not tested against the mutant, other
compounds in this chemical series show inhibition of
Thr315Ile Abl in the nanomolar range. The central phenyl ring
lies more than 1.2 A ˚ further away from Thr315 than the other
inhibitors reported here, which leaves enough space for an
extra methyl group (Fig. 5). The chemical structure of NVP-
AFG210 allows this relative displacement while retaining
hydrogen-bonding interactions with the hinge region. The
pyridine group forms one hydrogen bond to the backbone
nitrogen of Met318 and there is also a favourable interaction
between the pyridine CH and the main-chain carbonyl of
Glu316. The triﬂuoromethylbenzene binding in the DFG-out
pocket superimposes very well with the same group in other
inhibitors, despite the difference in the central part of the
inhibitor. The urea group forms hydrogen bonds with Glu286
and the main chain of Asp381, although only one of the N
atoms in the urea is participating. The medicinal chemistry for
a related series of urea-based compounds, which produced
potent inhibitors of Abl and PDGFR, has recently been
published (Manley, Breitenstein et al., 2004).
3.5.2. Conformational flexibility of the Abl kinase domain.
Superposition of the various structures reported here and one
recently reported structure (Levinson et al., 2006; PDB code
2g1t) shows that there are fourmain regions of conformational
ﬂexibility in the Abl kinase domain: the A-loop, the P-loop,
the C-helix and the relative position of the N-terminal lobe
with respect to the C-terminal lobe (Fig. 4). These confor-
mational differences cause changes in the properties of the
inhibitor-binding site and can be exploited to gain selectivity
while optimizing afﬁnity. With regard to the A-loop, the
conformation of the DFG motif has the greatest effect on the
binding pocket. There are now four main conformations
observed for this highly conserved structural element: the
active conformation, the DFG-out conformation, the DFG-
ﬂip conformation and the Src-like inactive conformation
(Fig. 4, Table 3). A recent publication used molecular-
dynamics simulations to show that the Src-like inactive
conformation of Abl kinase might be an intermediate step in
the transition between the active and inactive conformations
of the DFG motif; however, the DFG-ﬂip conformation was
not mentioned in this work (Levinson et al., 2006). When
comparing the surfaces of the various structures, it can be seen
that there are small pockets under the C-helix in the structure
with the DFG motif in the active conformation (NVP-AFN941
complex) and these are larger in the structure with the ﬂipped
conformation of the DFG motif (PD180970), suggesting that
this could also be an intermediate state between the active and
DFG-out conformations (Fig. 6). The backbone ’ and  
angles of the residues deﬁning the DFG-motif conformations
show that the major difference between the DFG-ﬂip
conformation and the others is a rotation of about 70 about
the Ala380 ’ angle, while the Asp381 angles are somewhere
between the DFG-out and the Src-like inactive conformations
and the Phe382 angles are much the same as the Src-like
inactive conformation. With regard to inhibitor binding, the
DFG-ﬂip conformation allows Phe382 to make interactions
with the inhibitor and changes the shape of the binding site
(Fig. 6c).
The conformation of the P-loop has an effect on the prop-
erties of the inhibitor-binding site at the entrance of the ATP
pocket (left-hand side of the binding site in the ﬁgures). In the
cases where the P-loop forms a cage around the inhibitors, the
entrance is almost closed (Figs. 6a and 6b), while in the NVP-
AFN941 complex it adopts an active conformation and is
partially disordered, so the entrance is quite open (Fig. 6d).
The NVP-AEG082 complex has the extended conformation of
the P-loop typical of the active conformation, but the entrance
to the ATP site looks quite closed compared with the other
complexes. This is because Phe382 of the DFG motif adopts a
conformation similar to that observed in the c-Kit–imatinib
complex, where it extends across underneath the P-loop
toward the entrance of the ATP pocket and forms a hydro-
phobic surface that is complementary to the shape of the
inhibitor. NVP-AEG082 does not extend far toward the
entrance of the ATP pocket, so does not require space in this
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Table 3
Backbone torsion angles that deﬁne the conformation of the DFG motif.
’ and   angles are based on averages (to the nearest 10) from structures
reportedin this article,except when the PDBcodeis mentioned explicitly. 2g1t
is the structure of Abl in an Src-like inactive conformation and the 2g2h
entries show slight variations of the DFG-ﬂip conformation (Levinson et al.,
2006). DFG-ﬂip conformations are also seen in PDB entries 1m52, 1opk and
1opl.
Ala380 Asp381 Phe382
DFG conformation ’ ()   () ’ ()   () ’ ()   ()
Active (n =3 ) 130 180 60 80 90 10
DFG-out (n =7 ) 140 170 150 110 90 10
DFG-ﬂip (n =2 ) 70 140 120 20 70 150
2g1t (n =2 ) 130 170 50 40 70 130
2g2h-A (n =1 ) 70 140 120 20 80 30region like NVP-AFN941. These observations tend to suggest
that the shape of the pocket created by the P-loop is corre-
lated with the conformation of the DFG motif, which is true
when they contact each other in the structures.
All of the compounds reported here occupy different parts
of the binding site. For example, the dichlorophenyl group of
PD180970 has a very good ﬁt to the pocket lined by the
gatekeeper residue, which is not used by NVP-AFN941.
Imatinib ﬁlls this region with a methylbenzene group in a very
similar way to PD180970, while AEG082 also ﬁts it well owing
to the ortho substitution pattern of the benzene ring. NVP-
AEG082 and NVP-AFG210 have an excellent ﬁt to the DFG-
out pocket, while imatinib does not have good shape
complementarity in this region and NVPAFN941 and
PD180970 do not use this pocket at all. A comparison of the
way different chemotypes use the binding site allows the
design of new structures that use all the subsites in the most
effective way, which can be used to gain afﬁnity and selectivity
(for an example, see Liu & Gray, 2006).
3.6. Structures to support chemical optimization
Based on the structures of imatinib and other lead series
bound to Abl kinase, many suggestions were made for
synthesis of new and improved compounds with the aim of
gaining potency and at least retaining selectivity. Only one of
these paths will be brieﬂy presented here. Four different
groups were proposed to take advantage of the hydrogen
bonds observed for the amide group of inhibitors to Glu286
and Ala381. The formation of an amide, a reverse amide, a
sulfonamide and a urea were the basis of the creation of
chemical libraries to explore binding in the DFG-out pocket,
while retaining the methylphenyl-(pyridinyl-pyrimidinyl)-
amine moiety of imatinib in the ATP pocket (Manley,
Breitenstein et al., 2004).
Compounds giving IC50 values against c-Abl in the nano-
molar range were found for each series except for the
sulfonamides, where all inhibitors were inactive. Structures
were determined for some of these potent inhibitors and were
used as a basis for ideas to support the optimization of
chemical properties such as chemical stability, metabolic
stability and solubility while retaining afﬁnity (Manley et al.,t o
be published; Manley, Breitenstein et al., 2004). Incorporation
of a hydroxyl group into the reverse-amide series to target
Asp381 gave a compound (NVP-AHT202) having an excellent
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Figure 6
Comparison of the surfaces for all ﬁve structures reported here. The inhibitor is shown with solid sticks (C, yellow; N, blue; O, red; Cl, green; F, cyan) and
the solvent-accessible surface is coloured according to the atom type that forms it (C, white; N, blue; O, red; S,orange). The surface is transparent to show
the buried parts of the binding site, which are darker for the same reason. The C
  trace of the protein is shown with white lines. (a) Imatinib, (b) NVP-
AFN941, (c) PD180970, (d) NVP-AEG082, (e) NVP-AFG210.
Figure 7
Superposition of the structures of imatinib (magenta) and nilotinib
(green) as bound to Abl kinase (cyan and grey, respectively). Potential
hydrogen bonds are shown as dotted red lines for the imatinib complex
and dotted grey lines for the nilotinib complex.kinase inhibition proﬁle but poor drugability characteristics
(Manley et al., to be published). The investigation of alter-
native donor/acceptor groups ﬁnally led to the synthesis of
NVP-AMN107 (nilotinib), which is highly potent, very selec-
tive and active against all but one of the resistance mutants
isolated from relapsed imatinib patients, has good pharma-
cokinetic properties and is now in clinical trials in man
(Weisberg et al., 2006; Kantarjian et al., 2006). Structures of
nilotinib in complex with Abl show that it makes similar
hydrogen-bonding interactions to imatinib with Abl kinase,
except for those formed by the N-methylpiperazine group of
imatinib to the C-terminal lobe (Fig. 7; Weisberg et al., 2005).
Nilotinib has a better ﬁt to the DFG-out pocket than imatinib,
which probably accounts largely for its increased afﬁnity.
There is also a weak electrostatic interaction between a
ﬂuorine from the triﬂuoromethyl group of nilotinib and the
polarized C atom of the Ala380 carbonyl group (Manley,
Cowan-Jacob, Fendrich et al., 2005). Its ability to inhibit most
of the imatinib-resistant mutants is most likely to primarily be
a consequence of the increased afﬁnity of nilotinib compared
with imatinib, allowing it to overcome the slight shift of the
equilibrium between the inactive and active states of the
enzyme towards the active state.
4. Conclusions
As stated by Levinson et al. (2006), working with an unphos-
phorylated protein seems to allow the sampling of numerous
possible conformational states. Phosphorylation will stabilize
an active conformation, but the binding of an inhibitor or even
the presence of different types of crystal environments can
stabilize the active and other conformations of the unphos-
phorylated protein. Working with unphosphorylated protein
does not preclude observing the active conformation. It is
even possible to isolate a protein in two different conforma-
tional states,or different ligation states,within the same crystal
(e.g. the NVP-AFN941 complex reported here; Levinson et al.,
2006). An examination of the different conformational states
of Abl kinase has lead to an excellent understanding of the
features of the binding important for potency, selectivity and
susceptibility to resistance.
After imatinib became the ﬁrst successful small-molecule
kinase inhibitor to reach the market (Capdeville et al., 2002),
publication of the ﬁrst structure of Abl kinase (Schindler et al.,
2000) and recognition that mutant Bcr-Abl was a key
mechanism of imatinib resistance (Shah et al., 2002), the race
was on to use structural biology to help ﬁnd even better
treatments for CML. As a result, the structural biology
program experienced considerable pressure to obtain novel
structures quickly. This pressure is further emphasized by the
large number of publications, illustrating the competitive
nature of the ﬁeld. In order to obtain the structural results
rapidly, the use of protein produced from multiple constructs,
the use of crystallization robotics and the use of partially
automated software was important. The availability of struc-
tures and especially the fact that these structures showed a
mode of binding that was not predicted by homology model-
ling at the time, considerably improved understanding of how
the drug worked. Follow-up structures of different Abl kinase
conformations induced by inhibitors with a variety of
chemotypes provided a basis for de novo design, database
mining and virtual screening to ﬁnd new chemical structures
which could bind to Abl. X-ray analysis of crystalline
complexes of these leads bound to the Abl kinase domain then
provided details of the binding modes of these new chemo-
types, which allowed further optimization of their structures
for potency against Bcr-Abl and its mutants, selectivity over
other kinases and general drugability properties. Structural
biology was a strong contributor to the quick discovery of
nilotinib (NVP-AMN107), which was ﬁrst synthesized in 2002
and went into ﬁrst clinical trials in 2005 (Kantarjian et al.,
2006).
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